Drug intelligence / Profile preview

fluoxetine + lamotrigine

Development stage
Preclinical
Lead developer
Eli Lilly
Modality
Small Molecules
Administration
Oral
01

Overview

Fluoxetine + lamotrigine is a combination of two pharmaceutical drugs used together, most commonly in psychiatric practice. Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) antidepressant that increases synaptic serotonin levels by inhibiting its reuptake into presynaptic neurons. Lamotrigine is an anticonvulsant and mood stabilizer that inhibits voltage-sensitive sodium channels, thereby stabilizing neuronal membranes and modulating the release of excitatory neurotransmitters such as glutamate. This combination has been reported in case studies for the treatment of conditions such as compulsive sexual behavior and may be considered in complex mood or impulse control disorders where both antidepressant and mood-stabilizing effects are desired[3]. The combination requires careful monitoring due to potential pharmacokinetic interactions (fluoxetine can increase blood levels of lamotrigine), risk of adverse effects including delirium or severe skin reactions like Stevens-Johnson syndrome[1][2][4][6].

Other names
fluoxetine and lamotriginelamotrigine and fluoxetine
02

Targets

NaV (Voltage-gated sodium channels)SERT (Sodium-dependent serotonin transporter)

Beyond the preview

Go deeper on fluoxetine + lamotrigine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on fluoxetine + lamotrigine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call